CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
加拿大弥漫大 B 细胞淋巴瘤治疗中双特异性抗体的优化使用
英文原题：Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.
查看英文原题
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法显著改善了复发/难治性（R/R）弥漫大 B 细胞淋巴瘤（DLBCL）患者的结局，但资源有限、制备周期和显著毒性等挑战仍然存在。双特异性抗体（BsAb），包括 glofitamab 和 epcoritamab，已显示出有前景的疗效，可为不适合 CAR-T 治疗或 CAR-T 治疗后复发的患者提供新选择。双特异性抗体的安全性特征可管理，且通常比 CAR-T 治疗更容易获得。本文中的病例讨论展示了 BsAb 在真实世界中的潜在应用，凸显其在治疗 CAR-T 后复发或无法接受 CAR-T 患者中的作用。总体而言，glofitamab 和 epcoritamab 是 R/R DLBCL 不断发展的治疗格局中的宝贵选择。
展开英文摘要原文
CAR-T cell therapy has significantly improved outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist. Bispecific antibodies (BsAbs), including glofitamab and epcoritamab, have demonstrated promising efficacy and represent a new treatment option in patients who are unsuitable for or have relapsed following CAR-T therapy.
Bispecific antibodies have a manageable safety profile and are generally more widely accessible than CAR-T cell therapy. Case discussions in this paper illustrate the potential real-world application of BsAbs, highlighting their role in treating patients who have relapsed after or are unable to undergo CAR-T cell therapy.
Overall, glofitamab and epcoritamab represent valuable treatment options in the evolving landscape of R/R DLBCL.
论文信息
- 作者
- Fleury I、MacDonald D、Shafey M、Christofides A、Sehn LH
- 第一作者单位
- Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, University of Montreal, Montreal, QC H3T 1J4, Canada.Canada
- 通讯作者单位
- BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, BC V6T 1Z2, Canada.Canada
- 文献类型
- 综述
- 期刊
- Current oncology (Toronto, Ont.)2025 Feb 28
- 原文标识
- PubMed 40136346 · DOI 10.3390/curroncol32030142
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →